Sixth Element leads £4m series-A for Azeria
Sixth Element Capital has led a £4m series-A funding round for Cambridge-based cancer drug discovery company Azeria Therapeutics.
The company plans to use the fresh capital to further develop its drug discovery programme and advance its research towards clinical trials.
Sixth Element deployed capital from its £70m CRT Pioneer Fund, which makes investments in companies engaged in drug discovery and clinical developments in the field of cancer. The vehicle was launched in 2012 and is backed by the European Investment Fund and the UK's Cancer Research Technology.
Company
Azeria was established in 2017 by Sixth Element Capital and Cancer Research UK. The company is based in Cambridge and specialises in developing breakthrough treatments for hormone-resistant breast and prostate cancer patients.
Using its proprietary drug screening platform, Azeria is developing a pipeline of small molecules designed to selectively inhibit pioneer factors shown to be pivotal in tumor development and which underpin drug resistance in cancer.
People
Azeria Therapeutics – Jason Carroll (founder, chief scientific officer).
Sixth Element Capital – Stephen Myatt (partner).
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater